| IMP1 is an oncogenic factor that is involved in promoting elevated proliferation by stabilizing the c-myc mRNA in ovarian carcinoma cells. | ovarian, |
| Data demonstrate that IGF2BP1 is a potential oncogene and an independent negative prognostic factor in neuroblastoma. | neuroblastoma, |
| IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. | neuroblastoma, |
| 35 SRF/IGF2BP1-dependent genes showing conserved association with SRF and IGF2BP1 expression indicate a poor overall survival probability in ovarian, liver and lung cancer. In conclusion, these findings identify the SRF/IGF2BP1-, miRNome- and m6A-dependent control of gene expression as a conserved oncogenic driver network in cancer. | liver,ovarian,lung, |
| Study found that IGF2BP1 was upregulated and associated with a poor prognosis in pancreatic cancer patients. Downregulation of IGF2BP1 inhibited pancreatic cancer cell growth in vitro and in vivo via the AKT signaling pathway. Upregulation of IGF2BP1 was attributed to the downregulation of miR-494 expression in pancreatic cancer and reexpression of miR-494 could partially abrogate the oncogenic role of IGF2BP1. | pancreatic, |
| IGF2BP1 is a potent oncogenic factor that regulates the adhesion, migration and invasiveness of tumor cells by modulating intracellular signaling. | None |
| Two KH domains of CRD-BP are required for efficient binding to oncogenic mRNAs and for granule formation in zebrafish embryos. | None |